Nephrology. |Renal Function Assessment.

GFR — One of the most important markers for identifying impaired renal function

  • Chronic kidney disease (CKD) is a common consequence of many medical conditions, and it's prevalence is rising.​​​​
  • Hypertension and diabetes mellitus — two main CKD causes. 
  • Glomerular Filtration Rate (GFR) is one of the most common tests used, and included in all standard blood panels assessing kidney function. 

Currently, GFR determination is based on an estimation using clinical data and blood based biomarkers such as creatinine. GFR can either be measured (mGFR) by tracer based methods or estimated (eGFR) using clinical data and blood based biomarkers such as creatinine or cystatin C. However, mGFR methods are highly elaborate and time-consuming and eGFR lacks accuracy in a variety of common clinical situations. As a consequence clinical decision making is difficult especially early when intervention may retard progression to end-stage renal disease.

 

1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.

Testing tube with metabolic network in liquid

New Renal Function Assay. |<i>AXINON<sup>&reg;</sup></i> System.

Precision Diagnostics.

Female Axinon system user in laboratory environment

This new kidney function assay combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.

A single result from this biomarker constellation generates a more accurate GFR result compared to standard eGFR equations.

  • Improves Accuracy: More closely correlates with measured GFR (mGFR) compared to traditional GFR equations
  • Overcomes Bias: Accounts for non-renal factors, i.e., comorbidities, age, race, BMI and muscle mass
  • Provides a Clearer Picture of GFR Status: Increases accuracy and confidence in kidney function research
  • Uses Exploratory Biomarker Mining: Enhances personalized medicine research

Frontiers | Serum myo-inositol and valine improve metabolomic-based estimated glomerular filtration rate among kidney transplant recipients (frontiersin.org)

Selected PublicationsMeeusen J, Stämmler F, Dasari S, et al. (2022). Front. Med. 9:988989. Fuhrmann M, Santamaria A, Scott, R, et al. (2022). Diagnostics 2022, 12(5), 1120. Stämmler F, Grassi M, Meeusen JW, et al. (2021). Diagnostics (Basel). 2021 Dec 7;11(12):2291. Ehrich J, Dubourg L, Hansson S, et al. (2021). Diagnostics (Basel). 2021 Feb 3;11(2):234
 
FDA 510(k) pending and available as CE-labeled IVD in the EU.

Go to FAQs
Axinon system with implemented and expandable test overview

Technology. |<i>AXINON<sup>&reg;</sup> System</i>.

Easy. Fast. Efficient.

Million analyses worldwide using numares technology

Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.

For GFR(NMR), the generated signals from serum samples corresponds with concentrations of the targeted metabolites with results reported in mL/minute/1.73 m2.

Our FDA-cleared AXINON® System is the core technology platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases. This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.

To date, more than 3 million tests have been performed worldwide using Numares technology.

Technology

* For Research Use only in the United States. Numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content